From Cell Death and Activation to Paralysis: Dysregulated Conventional Dendritic Cells in SIRS , Sepsis and Major Trauma Promote Immunosuppression
Immunological Reviews · 2026-01 · 337 (1)
DOI: 10.1111/imr.70087 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 11.01.2026. Verfasst von Mitra Ashayeripanah und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria, Aust…. Hauptthemen laut MEDLINE: Dendritic Cells, Systemic Inflammatory Response Syndrome, Sepsis, Immune Tolerance. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 266 Literaturangaben. Gefördert von: National Health and Medical Research Council of Australia.
Themen: Sepsis
Abstract (Originalsprache)
Conventional dendritic cells (cDC) are pivotal for initiating antigen‐specific T‐cell responses. Upon encountering pathogen‐ and damage‐associated molecular patterns (PAMPs/DAMPs) or inflammation, cDC undergo direct or indirect activation . Directly activated cDC acquire additional antigens and present them to prime T‐cells but become unresponsive to new antigens. In contrast, indirectly activated cDC remain capable of efficient antigen presentation upon subsequent exposure to PAMPs/DAMPs. Due to cDC's short lifespan, activated cDC are replenished within days by newly generated immature/resting cDC. However, during systemic inflammatory response syndrome (SIRS), early depletion and systemic activation of cDC can occur, followed by prolonged reprogramming that yields functionally impaired or paralyzed/regulatory cDC. These dysfunctional cDC populations contribute to post‐SIRS immunosuppression. Gradual resolution of the immunoregulatory microenvironment allows repopulation with functionally competent cDC over subsequent weeks or months, necessary for restoring immunocompetence. In this review, we summarize current understanding of the sequential alterations in cDC population during SIRS, sepsis, and major trauma. We discuss the mechanistic basis of cDC dysfunction in these conditions as well as in tumors, highlighting shared and distinct pathways of dysregulation. We further elaborate on emerging therapeutic strategies aimed at restoring cDC function to improve immune recovery and clinical outcomes in critically ill patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria, Australia.
- Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France.
- CHU Nantes, INSERM, Nantes Université, Anesthesie Reanimation, Nantes, France.
- Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria, Australia.
ORCID-Profile: Mitra Ashayeripanah, Jose Villadangos
Förderung
- National Health and Medical Research Council of Australia
Zitieren
APA
Ashayeripanah, M., Roquilly, A., & Villadangos, J. (2026). From Cell Death and Activation to Paralysis: Dysregulated Conventional Dendritic Cells in SIRS , Sepsis and Major Trauma Promote Immunosuppression. Immunological Reviews, 337(1). https://doi.org/10.1111/imr.70087
Vancouver
Ashayeripanah M, Roquilly A, Villadangos J. From Cell Death and Activation to Paralysis: Dysregulated Conventional Dendritic Cells in SIRS , Sepsis and Major Trauma Promote Immunosuppression. Immunological Reviews. 2026;337(1). doi:10.1111/imr.70087
BibTeX
@article{Ashayeripanah2026,
author = {Ashayeripanah, Mitra and Roquilly, Antoine and Villadangos, Jose},
title = {From Cell Death and Activation to Paralysis: Dysregulated Conventional Dendritic Cells in SIRS , Sepsis and Major Trauma Promote Immunosuppression},
journal = {Immunological Reviews},
year = {2026},
volume = {337},
number = {1},
doi = {10.1111/imr.70087}
}
EUVIMED